Role of RAGE in Alzheimer’s Disease

Cellular and Molecular Neurobiology

Volumn 36, Issue 4, 2016, Pages 483-495

  Cai, Zhiyou ^a   Liu, Nannuan ^a   Wang, Chuanling ^a   Qin, Biyong ^a   Zhou, Yingjun ^a   Xiao, Ming ^b   Chang, Liying ^c   Yan, Liang Jun ^d   Zhao, Bin ^e  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c HUBEI UNIVERSITY OF ARTS AND SCIENCE   (China)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^e GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Beta amyloid; Cognitive impairment; Receptor for advanced glycation end products; Tau hyperphosphorylation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; AMYLOID BETA PROTEIN; BETA SECRETASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYTOKINE; GAMMA SECRETASE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; OLIGOMER; PF 4494700; PROTEIN S100B; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; ADVANCED GLYCATION END PRODUCT; AMYLOID;

ALZHEIMER DISEASE; AMYLOID PLAQUE; APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN INTERSTITIAL FLUID; COGNITIVE DEFECT; ENERGY METABOLISM; HUMAN; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEADY STATE; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM; PATHOLOGY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ALZHEIMER DISEASE; AMYLOID; ANIMALS; COGNITIVE DYSFUNCTION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS;

EID: 84969497763     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-015-0233-3     Document Type: Review

References (141)

1. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, Bugiani O, Del-Tredici K, Ferrer I, Gelpi E et al (2008) Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe Consortium. Brain Pathol 18:484–496
2. Alves J, Magalhaes R, Arantes M, Cruz S, Goncalves OF, Sampaio A (2015) Cognitive rehabilitation in a visual variant of Alzheimer’s disease. Appl Neuropsychol Adult 22:73–78
3. Baiguera S, Fioravanzo L, Grandi C, Di LR, Parnigotto PP, Folin M (2009) Involvement of the receptor for advanced glycation-end products (RAGE) in beta-amyloid-induced toxic effects in rat cerebromicrovascular endothelial cells cultured in vitro. Int J Mol Med 24:9–15
4. Barroso E, Del Valle J, Porquet D, Vieira Santos AM, Salvado L, Rodriguez-Rodriguez R, Gutierrez P, Anglada-Huguet M, Alberch J, Camins A et al (2013) Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARbeta/delta-null mice. Biochim Biophys Acta 1832:1241–1248
5. Bellucci A, Rosi MC, Grossi C, Fiorentini A, Luccarini I, Casamenti F (2007) Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiol Dis 27:328–338
6. Bidzan M, Bidzan L (2014) Neurobehavioral manifestation in early period of Alzheimer disease and vascular dementia. Psychiatr Pol 48:319–330
7. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876–886
8. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW (2005) Tau, tangles, and Alzheimer’s disease. Biochim Biophys Acta 1739:216–223
9. Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, Piantelli M, Di IC, Consoli A, Sensi SL (2013) Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis 4:e612
10. Bonetti TC, Borges E Jr, Braga DP, Iaconelli A Jr, Kleine JP, Silva ID (2013) Intrafollicular soluble receptor for advanced glycation end products (sRAGE) and embryo quality in assisted reproduction. Reprod Biomed Online 26:62–67
11. Caldeira GL, Ferreira IL, Rego AC (2013) Impaired transcription in Alzheimer’s disease: key role in mitochondrial dysfunction and oxidative stress. J Alzheimers Dis 34:115–131
12. Carnevale D, Mascio G, D’Andrea I, Fardella V, Bell RD, Branchi I, Pallante F, Zlokovic B, Yan SS, Lembo G (2012) Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 60:188–197
13. Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, Luehrs DC, Schmidt AM, Stern D, Yan SD et al (2005) RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta 1741:199–205
14. Chappey O, Dosquet C, Wautier MP, Wautier JL (1997) Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 27:97–108
15. Chavakis T, Bierhaus A, Nawroth PP (2004) RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 6:1219–1225
16. Chekir C, Nakatsuka M, Noguchi S, Konishi H, Kamada Y, Sasaki A, Hao L, Hiramatsu Y (2006) Accumulation of advanced glycation end products in women with preeclampsia: possible involvement of placental oxidative and nitrative stress. Placenta 27:225–233
17. Chen Z, Zhong C (2013) Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108:21–43
18. Chen X, Zhang T, Du G (2008) Advanced glycation end products serve as ligands for lectin-like oxidized low-density lipoprotein receptor-1(LOX-1): biochemical and binding characterizations assay. Cell Biochem Funct 26:760–770
19. Chen S, An FM, Yin L, Liu AR, Yin DK, Yao WB, Gao XD (2014) Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience 256:137–146
20. Choi BR, Cho WH, Kim J, Lee HJ, Chung C, Jeon WK, Han JS (2014) Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer’s disease. Exp Mol Med 46:e75
21. Chuah YK, Basir R, Talib H, Tie TH, Nordin N (2013) Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam 2013:403460
22. Cohen MM Jr (2013) Perspectives on RAGE signaling and its role in cardiovascular disease. Am J Med Genet A 161A:2750–2755
23. Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, Castellano A, Pifferi F, Bocti C, Paquet N et al (2011) Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition 27:3–20
24. Dai Y, Kamal MA (2014) Fighting Alzheimer’s disease and type 2 diabetes: pathological links and treatment strategies. CNS Neurol Disord 13:271–282
25. Dar TA, Sheikh IA, Ganie SA, Ali R, Singh LR, Gan SH, Kamal MA, Zargar MA (2014) Molecular linkages between diabetes and Alzheimer’s disease: current scenario and future prospects. CNS Neurol Disord 13:290–298
26. de la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol 88:548–559
27. de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, Bandopadhyay R, Utton M, Strand C, Jowett T et al (2003) Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 29:288–302
28. Di BB, Li HW, Li WP, Shen XH, Sun ZJ, Wu X (2015) Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells. Mol Med Rep 11:2601–2607
29. Dobarro M, Gerenu G, Ramirez MJ (2013) Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer’s transgenic mice. Int J Neuropsychopharmacol 16:2245–2257
30. Durany N, Munch G, Michel T, Riederer P (1999) Investigations on oxidative stress and therapeutical implications in dementia. Eur Arch Psychiatry Clin Neurosci 249((Suppl 3)):68–73
31. Esposito G, Scuderi C, Lu J, Savani C, De Filippis D, Iuvone T, Steardo L Jr, Sheen V, Steardo L (2008) S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med 12:914–927
32. Faden AI, Loane DJ (2014) Chronic neurodegeneration after traumatic brain injury: Alzheimer disease, chronic traumatic encephalopathy, or persistent neuroinflammation. Neurotherapeutics. 12:143–150
33. Farmer DG, Ewart MA, Mair KM, Kennedy S (2014) Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hypoxia in the mouse. Pulm Pharmacol Ther 29:7–14
34. Fernandez JA, Rojo L, Kuljis RO, Maccioni RB (2008) The damage signals hypothesis of Alzheimer’s disease pathogenesis. J Alzheimers Dis 14:329–333
35. Franko B, Brault J, Jouve T, Beaumel S, Benhamou PY, Zaoui P, Stasia MJ (2014) Differential impact of glucose levels and advanced glycation end-products on tubular cell viability and pro-inflammatory/profibrotic functions. Biochem Biophys Res Commun. 451:627–631
36. Fuster-Matanzo A, Llorens-Martin M, Hernandez F, Avila J (2013) Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediators Inflamm 2013:260925
37. Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS (2014) Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology 82:1536–1542
38. Gasparotto J, Senger MR, Kunzler A, Degrossoli A, de Simone SG, Bortolin RC, Somensi N, Girardi CS, de Souza Cda S, Calabrese KS et al (2015) Increased tau phosphorylation and receptor for advanced glycation endproducts (RAGE) in the brain of mice infected with Leishmania amazonensis. Brain Behav Immun 43:37–45
39. Heilmann RM, Otoni CC, Jergens AE, Grutzner N, Suchodolski JS, Steiner JM (2014) Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease. Vet Immunol Immunopathol 161:184–192
40. Hoyer S (2000) Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 35:1363–1372
41. Iacono D, Resnick SM, O’Brien R, Zonderman AB, An Y, Pletnikova O, Rudow G, Crain B, Troncoso JC (2014) Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent beta-amyloid and tau loads with divergent cognitive outcomes. J Neuropathol Exp Neurol 73:295–304
42. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci 33:1024–1037
43. Isono T, Yamashita N, Obara M, Araki T, Nakamura F, Kamiya Y, Alkam T, Nitta A, Nabeshima T, Mikoshiba K et al (2013) Amyloid-beta(2)(5)(-)(3)(5) induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2. Neurosci Res 77:180–185
44. Kalousova M, Zima T (2014) AGEs and RAGE—advanced glycation end-products and their receptor in questions and answers. Vnitr Lek 60:720–724
45. Kapogiannis D, Mattson MP (2011) Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer’s disease. Lancet Neurol 10:187–198
46. Kenessey A, Nacharaju P, Ko LW, Yen SH (1997) Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J Neurochem 69:2026–2038
47. Kook SY, Seok HH, Moon M, Mook-Jung I (2013) Disruption of blood-brain barrier in Alzheimer disease pathogenesis. Tissue Barriers 1:e23993
48. Kosenko EA, Solomadin IN, Tikhonova LA, Reddy VP, Aliev G, Kaminsky YG (2014) Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid-beta peptides, systemic ammonia and erythrocyte energy metabolism. CNS Neurol Disord 13:112–119
49. Krautwald M, Munch G (2010) Advanced glycation end products as biomarkers and gerontotoxins—A basis to explore methylglyoxal-lowering agents for Alzheimer’s disease. Exp Gerontol 45:744–751
50. Kuhla A, Ludwig SC, Kuhla B, Munch G, Vollmar B (2014) Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer’s disease brain. Neurobiol Aging 36:753–761
51. Kuwahara H, Nishida Y, Yokota T (2013) Blood-brain barrier and Alzheimer’s disease. Brain and nerve = Shinkei kenkyu no shinpo 65:145–151
52. Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, et al (2014) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers Dement
53. Lee G, Cowan N, Kirschner M (1988) The primary structure and heterogeneity of tau protein from mouse brain. Science 239:285–288
54. Lee YS, Kim H, Kim YH, Roh EJ, Han H, Shin KJ (2012) Synthesis and structure-activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett 22:7555–7561
55. Leuner K, Muller WE, Reichert AS (2012) From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer’s disease. Mol Neurobiol 46:186–193
56. Li J, Liu D, Sun L, Lu Y, Zhang Z (2012a) Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci 317:1–5
57. Li K, Dai D, Zhao B, Yao L, Yao S, Wang B, Yang Z (2010) Association between the RAGE G82S polymorphism and Alzheimer's disease. J Neural Transm 117:97–104
58. Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ (2012b) AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 33:1400–1410
59. Li XH, Xie JZ, Jiang X, Lv BL, Cheng XS, Du LL, Zhang JY, Wang JZ, Zhou XW (2012c) Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation. Neuromolecular Med. 14:338–348
60. Li XH, Du LL, Cheng XS, Jiang X, Zhang Y, Lv BL, Liu R, Wang JZ, Zhou XW (2013) Glycation exacerbates the neuronal toxicity of beta-amyloid. Cell Death Dis 4:e673
61. Liang F, Jia J, Wang S, Qin W, Liu G (2013) Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer’s disease. J Clin Neurosci 20:357–361
62. Liu R, Wu CX, Zhou D, Yang F, Tian S, Zhang L, Zhang TT, Du GH (2012) Pinocembrin protects against beta-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis. BMC Med 10:105
63. Liu R, Li JZ, Song JK, Zhou D, Huang C, Bai XY, Xie T, Zhang X, Li YJ, Wu CX et al (2014) Pinocembrin improves cognition and protects the neurovascular unit in Alzheimer related deficits. Neurobiol Aging 35:1275–1285
64. Lue LF, Walker DG, Jacobson S, Sabbagh M (2009) Receptor for advanced glycation end products: its role in Alzheimer’s disease and other neurological diseases. Future Neurol 4:167–177
65. Lukiw WJ (2012) NF-kappaB-regulated, proinflammatory miRNAs in Alzheimer’s disease. Alzheimers Res Ther 4:47
66. Luth HJ, Ogunlade V, Kuhla B, Kientsch-Engel R, Stahl P, Webster J, Arendt T, Munch G (2005) Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer’s disease brains. Cereb Cortex 15:211–220
67. Lv C, Wang L, Liu X, Yan S, Yan SS, Wang Y, Zhang W (2015) Multi-faced neuroprotective effects of geniposide depending on the RAGE-mediated signaling in an Alzheimer mouse model. Neuropharmacology 89:175–184
68. Mahboobi H, Golmirzaei J, Gan SH, Jalalian M, Kamal MA (2014) Humanin: a possible linkage between Alzheimer’s disease and type 2 diabetes. CNS Neurol Disord 13:543–552
69. Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C (2014) Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer’s disease and mild cognitive impairment: a pilot-study. Exp Gerontol 50:114–121
70. Matrone C, Djelloul M, Taglialatela G, Perrone L (2015) Inflammatory risk factors and pathologies promoting Alzheimer’s disease progression: is RAGE the key. Histol Histopathol 30:125–139
71. Moriya S, Yamazaki M, Murakami H, Maruyama K, Uchiyama S (2014) Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE. J Stroke Cerebrovasc Dis 23:2540–2546
72. Motoyoshi S, Yamamoto Y, Munesue S, Igawa H, Harashima A, Saito H, Han D, Watanabe T, Sato H, Yamamoto H (2014) cAMP ameliorates inflammation by modulation of macrophage receptor for advanced glycation end-products. Biochem J 463:75–82
73. Munch G, Thome J, Foley P, Schinzel R, Riederer P (1997) Advanced glycation endproducts in ageing and Alzheimer’s disease. Brain Res Brain Res Rev 23:134–143
74. Opatrna S, Popperlova A, Kalousova M, Zima T (2014) Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 proinflammatory ligands of receptor for advanced glycation end products. Ther Apher Dial 18:309–316
75. Perez SE, Raghanti MA, Hof PR, Kramer L, Ikonomovic MD, Lacor PN, Erwin JM, Sherwood CC, Mufson EJ (2013) Alzheimer’s disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla). J Comp Neurol 521:4318–4338
76. Perrone L, Grant WB (2015) Observational and ecological studies of dietary advanced glycation end products in national diets and Alzheimer’s disease incidence and prevalence. J Alzheimers Dis 45:965–979
77. Pertynska-Marczewska M, Merhi Z (2014) Relationship of advanced glycation end products with cardiovascular disease in menopausal women. Reprod Sci. 22:447–482
78. Piras S, Furfaro AL, Piccini A, Passalacqua M, Borghi R, Carminati E, Parodi A, Colombo L, Salmona M, Pronzato MA et al (2014) Monomeric Abeta1-42 and RAGE: key players in neuronal differentiation. Neurobiol Aging 35:1301–1308
79. Polydoro M, de Calignon A, Suarez-Calvet M, Sanchez L, Kay KR, Nicholls SB, Roe AD, Pitstick R, Carlson GA, Gomez-Isla T et al (2013) Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer’s disease. J Neurosci 33:13300–13311
80. Porsteinsson AP, Keltz MA, Smith JS (2014) Role of citalopram in the treatment of agitation in Alzheimer’s disease. Neurodegener Dis Manag 4:345–349
81. Pozueta J, Lefort R, Shelanski ML (2013) Synaptic changes in Alzheimer’s disease and its models. Neuroscience 251:51–65
82. Provias J, Jeynes B (2014) The role of the blood-brain barrier in the pathogenesis of senile plaques in Alzheimer’s disease. Int J Alzheimers Dis 2014:191863
83. Purushothuman S, Johnstone DM, Nandasena C, Mitrofanis J, Stone J (2014) Photobiomodulation with near infrared light mitigates Alzheimer’s disease-related pathology in cerebral cortex—evidence from two transgenic mouse models. Alzheimers Res Ther 6:2
84. Qosa H, LeVine H 3rd, Keller JN, Kaddoumi A (2014) Mixed oligomers and monomeric amyloid-beta disrupts endothelial cells integrity and reduces monomeric amyloid-beta transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. Biochim Biophys Acta 1842:1806–1815
85. Quade-Lyssy P, Kanarek AM, Baiersdorfer M, Postina R, Kojro E (2013) Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J Lipid Res 54:3052–3061
86. Qureshi HY, Li T, MacDonald R, Cho CM, Leclerc N, Paudel HK (2013) Interaction of 14-3-3zeta with microtubule-associated protein tau within Alzheimer’s disease neurofibrillary tangles. Biochemistry 52:6445–6455
87. Ramamurthy B, Larsson L (2013) Detection of an aging-related increase in advanced glycation end products in fast- and slow-twitch skeletal muscles in the rat. Biogerontology 14:293–301
88. Rapoport SI, Hatanpaa K, Brady DR, Chandrasekaran K (1996) Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease. Neurodegeneration 5:473–476
89. Rofina JE, Singh K, Skoumalova-Vesela A, van Ederen AM, van Asten AJ, Wilhelm J, Gruys E (2004) Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid 11:90–100
90. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D (2011) PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 25:206–212
91. Salahuddin P, Rabbani G, Khan RH (2014) The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach. Cell Mol Biol Lett 19:407–437
92. Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M (2011) AMP-activated protein kinase: a potential player in Alzheimer’s disease. J Neurochem 118:460–474
93. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R et al (1998) Advanced glycation end products in Alzheimer’s disease and other neurodegenerative diseases. Am J Pathol 153:1149–1155
94. Sato N, Takeda S, Uchio-Yamada K, Ueda H, Fujisawa T, Rakugi H, Morishita R (2011) Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr Aging Sci 4:118–127
95. Schmidt ML, Huang R, Martin JA, Henley J, Mawal-Dewan M, Hurtig HI, Lee VM, Trojanowski JQ (1996) Neurofibrillary tangles in progressive supranuclear palsy contain the same tau epitopes identified in Alzheimer’s disease PHFtau. J Neuropathol Exp Neurol 55:534–539
96. Semba RD, Gebauer SK, Baer DJ, Sun K, Turner R, Silber HA, Talegawkar S, Ferrucci L, Novotny JA (2014) Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J Nutr 144:1037–1042
97. Sharma HS, Castellani RJ, Smith MA, Sharma A (2012) The blood-brain barrier in Alzheimer’s disease: novel therapeutic targets and nanodrug delivery. Int Rev Neurobiol 102:47–90
98. Shemirani F, Yazdanparast R (2014) The interplay between hyperglycemia-induced oxidative stress markers and the level of soluble receptor for advanced glycation end products (sRAGE) in K562 cells. Mol Cell Endocrinol 393:179–186
99. Shin J, Lee SY, Kim SH, Kim YB, Cho SJ (2008) Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer’s disease. Neuroimage 43:236–244
100. Shin S, Kim JH, Cho JH, Kim GS, Choi SA, Lee JH (2014) Mild cognitive impairment due to Alzheimer disease is less likely under the age of 65. Alzheimer Dis Assoc Disord 29:26–31
101. Slowik A, Merres J, Elfgen A, Jansen S, Mohr F, Wruck CJ, Pufe T, Brandenburg LO (2012) Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)—and amyloid beta 1-42-induced signal transduction in glial cells. Mol Neurodegener 7:55
102. Smith MA, Monnier VM, Sayre LM, Perry G (1995) Amyloidosis, advanced glycation end products and Alzheimer disease. NeuroReport 6:1595–1596
103. Son SM, Jung ES, Shin HJ, Byun J, Mook-Jung I (2012) Abeta-induced formation of autophagosomes is mediated by RAGE-CaMKKbeta-AMPK signaling. Neurobiol Aging 33:1006 e11–23
104. Steele JW, Brautigam H, Short JA, Sowa A, Shi M, Yadav A, Weaver CM, Westaway D, Fraser PE, St GPH et al (2014) Early fear memory defects are associated with altered synaptic plasticity and molecular architecture in the TgCRND8 Alzheimer’s disease mouse model. J Comp Neurol 522:2319–2335
105. Stitt AW, Jenkins AJ, Cooper ME (2002) Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 11:1205–1223
106. Sugihara T, Munesue S, Yamamoto Y, Sakurai S, Akhter N, Kitamura Y, Shiba K, Watanabe T, Yonekura H, Hayashi Y et al (2012) Endogenous secretory receptor for advanced glycation end-products inhibits amyloid-beta1-42 uptake into mouse brain. J Alzheimers Dis 28:709–720
107. Tabaton M, Cammarata S, Manetto V, Perry G, Mancardi G (1989) Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer’s disease. Neurosci Lett 103:259–262
108. Takeuchi M, Yamagishi S (2008) Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer’s disease. Curr Pharm Des 14:973–978
109. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, Bucala R, Yamagishi S (2004) Involvement of advanced glycation end-products (AGEs) in Alzheimer’s disease. Curr Alzheimer Res 1:39–46
110. Takeuchi M, Sato T, Takino J, Kobayashi Y, Furuno S, Kikuchi S, Yamagishi S (2007) Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer’s disease. Med Hypotheses 69:1358–1366
111. Tancharoen S, Tengrungsun T, Suddhasthira T, Kikuchi K, Vechvongvan N, Tokuda M, Maruyama I (2014) Overexpression of receptor for advanced glycation end products and high-mobility group box 1 in human dental pulp inflammation. Mediators Inflamm 2014:754069
112. Tangen GG, Engedal K, Bergland A, Moger TA, Mengshoel AM (2014) Relationships between balance and cognition in patients with subjective cognitive impairment, mild cognitive impairment, and Alzheimer disease. Phys Ther 94:1123–1134
113. Thomas MC, Forbes JM, Cooper ME (2005) Advanced glycation end products and diabetic nephropathy. Am J Ther 12:562–572
114. Thome J, Kornhuber J, Munch G, Schinzel R, Taneli Y, Zielke B, Rosler M, Riederer P (1996) New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs). Nervenarzt 67:924–929
115. Tomoo K, Yao TM, Minoura K, Hiraoka S, Sumida M, Taniguchi T, Ishida T (2005) Possible role of each repeat structure of the microtubule-binding domain of the tau protein in in vitro aggregation. J Biochem 138:413–423
116. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N (2010) Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis 37:67–76
117. Verri M, Pastoris O, Dossena M, Aquilani R, Guerriero F, Cuzzoni G, Venturini L, Ricevuti G, Bongiorno AI (2012) Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer’s disease. Int J Immunopathol Pharmacol 25:345–353
118. Vicente MH, Outeiro TF (2010) The sour side of neurodegenerative disorders: the effects of protein glycation. J. Pathol. 221:13–25
119. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91:4766–4770
120. Wan W, Chen H, Li Y (2014) The potential mechanisms of Abeta-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer’s disease. Int J Neurosci 124:75–81
121. Wan W, Cao L, Liu L, Zhang C, Kalionis B, Tai X, Li Y, Xia S (2015) Abeta oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins. J Neurochem. doi:10.1111/jnc.13122
122. Wang CY, Xie JW, Xu Y, Wang T, Cai JH, Wang X, Zhao BL, An L, Wang ZY (2013) Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-kappaB pathway in a transgenic mouse model of Alzheimer’s disease. Antioxid Redox Signal 19:2024–2039
123. Wang X, Yu S, Hu JP, Wang CY, Wang Y, Liu HX, Liu YL (2014) Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-kappaB pathway. Int J Neurosci 124:601–608
124. Wautier MP, Tessier FJ, Wautier JL (2014) Advanced glycation end products: a risk factor for human health. Ann Pharm Fr 72:400–408
125. Webster B, Hansen L, Adame A, Crews L, Torrance M, Thal L, Masliah E (2006) Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J Neuropathol Exp Neurol 65:142–151
126. Xiao Z, Cilz NI, Kurada L, Hu B, Yang C, Wada E, Combs CK, Porter JE, Lesage F, Lei S (2014) Activation of neurotensin receptor 1 facilitates neuronal excitability and spatial learning and memory in the entorhinal cortex: beneficial actions in an Alzheimer’s disease model. J Neurosci 34:7027–7042
127. Xie C, Miyasaka T, Yoshimura S, Hatsuta H, Yoshina S, Kage-Nakadai E, Mitani S, Murayama S, Ihara Y (2014) The homologous carboxyl-terminal domains of microtubule-associated protein 2 and TAU induce neuronal dysfunction and have differential fates in the evolution of neurofibrillary tangles. PLoS ONE 9:e89796
128. Xu L, Zang P, Feng B, Qian Q (2014) Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats. Diabetol Metab Syndr 6:102
129. Xue J, Ray R, Singer D, Bohme D, Burz DS, Rai V, Hoffmann R, Shekhtman A (2014) The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry 53:3327–3335
130. Yamagishi SI, Fukami K, Matsui T (2015) Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc Diabetol 14:2
131. Yamagishi S, Matsui T (2010) Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2:1184–1195
132. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA et al (1994) Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91:7787–7791
133. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P et al (1995) Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1:693–699
134. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J et al (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 382:685–691
135. Yan SS, Chen D, Yan S, Guo L, Du H, Chen JX (2012) RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer’s disease. Front Biosci (Schol Ed) 4:240–250
136. Yang Y, Song W (2013) Molecular links between Alzheimer’s disease and diabetes mellitus. Neuroscience 250:140–150
137. Yoon SS, Jo SA (2012) Mechanisms of amyloid-beta peptide clearance: potential therapeutic targets for Alzheimer’s disease. Biomol Ther (Seoul) 20:245–255
138. Yu SL, Wong CK, Szeto CC, Li EK, Cai Z, Tam LS (2014) Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis. Lupus 24:675–686
139. Zhang MH, Feng L, Zhu MM, Gu JF, Jiang J, Cheng XD, Ding SM, Wu C, Jia XB (2014) The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and High-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats. J Ethnopharmacol 151:591–600
140. Zhou WW, Lu S, Su YJ, Xue D, Yu XL, Wang SW, Zhang H, Xu PX, Xie XX, Liu RT (2014) Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease. Free Radic Biol Med 74:50–63
141. Zong H, Madden A, Ward M, Mooney MH, Elliott CT, Stitt AW (2010) Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem 285:23137–23146